Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 1326
  • Home
  • Print this page
  • Email this page


 
   Table of Contents      
LETTER TO THE EDITOR
Year : 2019  |  Volume : 67  |  Issue : 8  |  Page : 1384-1385

Ophthalmic biosimilars: Lessons from India


1 Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India
2 Gavin Herbert Eye Institute, University of California, Irvine, CA, USA
3 Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy
4 Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Israel

Date of Web Publication22-Jul-2019

Correspondence Address:
Dr. Ashish Sharma
Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore - 641 014, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijo.IJO_430_19

Rights and Permissions

How to cite this article:
Sharma A, Kumar N, Kuppermann BD, Francesco B, Lowenstein A. Ophthalmic biosimilars: Lessons from India. Indian J Ophthalmol 2019;67:1384-5

How to cite this URL:
Sharma A, Kumar N, Kuppermann BD, Francesco B, Lowenstein A. Ophthalmic biosimilars: Lessons from India. Indian J Ophthalmol [serial online] 2019 [cited 2019 Aug 17];67:1384-5. Available from: http://www.ijo.in/text.asp?2019/67/8/1384/263143



Sir,

India has been on the forefront of biosimilar development for ophthalmic therapeutics by developing and commercially marketing Razumab® (Intas Pharmaceuticals, Ahmedabad, India), the first commercially available biosimilar to Ranibizumab (Leucentis®), an innovator molecule (Genentech, South San Francisco, CA, USA). Many other similar molecules are in the Reserach and Development (R&D) phase globally.[1] Razumab was approved for the Indian market in 2015 for clinical use and has grown its user base rapidly. This is reflected by the fact that the number of units sold in 2018 alone were almost equal to the total sale of Razumab since its launch. (Unpublished data from manufacturer).

Yet a major hindrance in the success of Razumab is the occurrence of adverse drug reaction (ADR) sterile endophthalmitis, being reported for specific batches of Razumab, putting a question on its safety.[2] ADR is an inherent part of any drug administration and has been reported in innovator molecules also.[3] However, cluster occurrence in specific batches of Razumab brings the interbatch variability to the limelight, and puts a question on the quality control. To counteract the nocebo about these complex molecules being perceived as generic drugs with lower safety and efficacy, stricter guidelines to validate the postapproval inter batch comparability of biosimilars should be enforced.

There are many potential ophthalmic biosimilar molecules which would be entering the global market in the next few years.[1] Manufacturers of these molecules can take the following lessons from India.

  1. There is a need of biosimilars especially in developing countries where the presence of compounding pharmacies is rare. It is an opportunity for ophthalmic biosimilar manufacturers globally.
  2. Strict pharmacovigilence and the careful choice of immunogenicity testing assay prior to market approval can reduce the nocebo effect around these molecules.[4]


Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Sharma A, Reddy P, Kuppermann BD, Bandello F, Loewenstein A. Biosimilars in ophthalmology: Is there a big change on the horizon? Clin Ophthalmol 2018;12:2137-43.  Back to cited text no. 1
    
2.
3.
Souied EH, Dugel PU, Ferreira A, Hashmonay R, Lu J, Kelly SP. Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: A retrospective claims database analysis. Ophthalmic Epidemiol 2016;23:71-9.  Back to cited text no. 3
    
4.
Sharma A, Kumar N, Kuppermann BD, Francesco B, Loewenstein A. Biotherapeutics and immunogenicity: ophthalmic perspective. Eye 2019 Apr 09.  Back to cited text no. 4
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed154    
    Printed1    
    Emailed0    
    PDF Downloaded71    
    Comments [Add]    

Recommend this journal